EP
Eversept Partners Portfolio holdings
AUM
$992M
1-Year Return
2.54%
This Quarter Return
+0.43%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$992M
AUM Growth
+$109M
(+12%)
Cap. Flow
+$89.1M
Cap. Flow
% of AUM
8.98%
Top 10 Holdings %
Top 10 Hldgs %
53.33%
Holding
74
New
18
Increased
22
Reduced
22
Closed
6
Top Buys
| 1 |
Vaxcyte
PCVX
|
+$24.1M |
| 2 |
Revvity
RVTY
|
+$20.4M |
| 3 |
UnitedHealth
UNH
|
+$18.9M |
| 4 |
Illumina
ILMN
|
+$18.9M |
| 5 |
Avantor
AVTR
|
+$18.9M |
Top Sells
| 1 |
HealthEquity
HQY
|
+$20.5M |
| 2 |
HCA Healthcare
HCA
|
+$20.1M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$18.5M |
| 4 |
Natera
NTRA
|
+$16.4M |
| 5 |
Protagonist Therapeutics
PTGX
|
+$14.9M |
Sector Composition
| 1 | Healthcare | 99.94% |
| 2 | Financials | 0.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Natera
NTRA
$23.3B
| $135M | 12.37% |
796,375
-97,346
| -11% | -$16.4M |
|
2
GSK
GSK
$81.5B
| $86.1M | 7.92% |
2,242,388
-380,858
| -15% | -$14.6M |
|
3
Vera Therapeutics
VERA
$1.55B
| $56.1M | 5.16% |
2,383,055
+484,251
| +26% | +$11.4M |
|
|
4
Revvity
RVTY
$9.58B
| $49.4M | 4.54% |
510,330
+211,243
| +71% | +$20.4M |
|
|
5
Vaxcyte
PCVX
$4.15B
| $42.2M | 3.88% |
1,298,514
+741,444
| +133% | +$24.1M |
|
|
6
HCA Healthcare
HCA
$92.3B
| $38.3M | 3.52% |
99,983
-52,519
| -34% | -$20.1M |
|
7
Syndax Pharmaceuticals
SNDX
$1.36B
| $38.1M | 3.5% |
4,065,355
-146,915
| -3% | -$1.38M |
|
8
Bruker
BRKR
$4.63B
| $34.6M | 3.18% |
839,284
+340,077
| +68% | +$14M |
|
9
Viridian Therapeutics
VRDN
$1.62B
| $26.6M | 2.45% |
1,902,539
+524,865
| +38% | +$7.34M |
|
10
Ionis Pharmaceuticals
IONS
$10.2B
| $23.3M | 2.14% |
588,900
+71,879
| +14% | +$2.84M |
|
11
Centene
CNC
$15.4B
| $21.6M | 1.99% |
398,726
+58,387
| +17% | +$3.17M |
|
12
Inspire Medical Systems
INSP
$2.33B
| $21.3M | 1.96% |
164,473
-21,952
| -12% | -$2.85M |
|
13
Community Health Systems
CYH
$409M
| $20.9M | 1.92% |
6,144,384
-2,313,636
| -27% | -$7.87M |
|
|
14
Avantor
AVTR
$8.6B
| $20.5M | 1.89% |
1,526,164
+1,403,341
| +1,143% | +$18.9M |
|
15
Bio-Techne
TECH
$7.93B
| $20.3M | 1.87% |
394,139
+114,022
| +41% | +$5.87M |
|
16
Travere Therapeutics
TVTX
$2.43B
| $19.5M | 1.79% |
1,315,033
+498,779
| +61% | +$7.38M |
|
17
ZimVie
ZIMV
$532M
| $19.4M | 1.79% |
2,079,380
| – | – |
|
|
18
UnitedHealth
UNH
$314B
| $18.9M | 1.74% |
+60,736
| New | +$18.9M |
|
|
19
Illumina
ILMN
$14.7B
| $18.9M | 1.74% |
+198,584
| New | +$18.9M |
|
20
Teva Pharmaceuticals
TEVA
$22.4B
| $17.6M | 1.62% |
1,052,881
-357,884
| -25% | -$6M |
|
21
Celldex Therapeutics
CLDX
$1.66B
| $17.1M | 1.57% |
838,736
+142,237
| +20% | +$2.89M |
|
22
United Therapeutics
UTHR
$17.9B
| $17.1M | 1.57% |
59,366
+1,877
| +3% | +$539K |
|
|
23
HealthEquity
HQY
$7.88B
| $16.3M | 1.5% |
155,868
-196,108
| -56% | -$20.5M |
|
24
IQVIA
IQV
$31.3B
| $15.4M | 1.41% |
+97,604
| New | +$15.4M |
|
|
25
Protagonist Therapeutics
PTGX
$3.59B
| $15.3M | 1.41% |
277,316
-269,800
| -49% | -$14.9M |
|